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ARTICLE
The 12q14 microdeletion syndrome: six new cases
confirming the role of HMGA2 in growth
Sally Ann Lynch*,1, Nicola Foulds2, Ann-Charlotte Thuresson3, Amanda L Collins2, Go¨ran Annere´n3,
Bernt-Oves Hedberg4, Carol A Delaney5, James Iremonger5, Caroline M Murray5, John A Crolla6,
Colm Costigan7, Wayne Lam8, David R Fitzpatrick8,9, Regina Regan10, Sean Ennis10 and Freddie Sharkey5
We report six patients with array deletions encompassing 12q14. Out of a total of 2538 array investigations carried out on
children with developmental delay and dysmorphism in three diagnostic testing centres, six positive cases yielded a frequency
of 1 in 423 for this deletion syndrome. The deleted region in each of the six cases overlaps significantly with previously reported
cases with microdeletions of this region. The chromosomal range of the deletions extends from 12q13.3q15. In the current
study, we report overlapping deletions of variable extent and size but primarily comprising chromosomal bands 12q13.3q14.1.
Four of the six deletions were confirmed as de novo events. Two cases had deletions that included HMGA2, and both children
had significant short stature. Neither case had osteopoikilosis despite both being deleted for LEMD3. Four cases had deletions
that ended proximal to HMGA2 and all of these had much better growth. Five cases had congenital heart defects, including two
with atrial septal defects, one each with pulmonary stenosis, sub-aortic stenosis and a patent ductus. Four cases had moderate
delay, two had severe developmental delay and a further two had a diagnosis of autism. All six cases had significant speech
delay with subtle facial dysmorphism.
European Journal of Human Genetics (2011) 19, 534–539; doi:10.1038/ejhg.2010.215; published online 26 January 2011
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INTRODUCTION
Chromosomal microdeletions and duplications are known to be a
significant cause of developmental delay and congenital malformation
in humans. In recent times, the impact of array-CGH technologies
has allowed the rapid identification and delineation of many new
syndromic conditions in patients with idiopathic learning disability
and congenital dysmorphism. Microdeletions of chromosomal region
12q14 have been associated with characteristic features that include
low birth weight, failure to thrive, short stature, developmental delay
and facial dysmorphism.1–4 To date, six cases with deletions spanning
this region and with similar phenotype have been reported as 12q14
microdeletion syndrome. Similar deletions have also been described
in children with features of Silver–Russell syndrome and/or
primordial dwarfism.4 The severe growth retardation in these cases
is thought to be due to loss of HMGA2 which lies within this region.
Osteopoikilosis, due to deletion of the LEMD3 gene, has been
described in some but not all cases reported to date.
We present a further six children with developmental delay
and array-CGH-detected deletions within 12q14. Two of the children
have deletions that included HMGA2 and LEMD3. The other four
have deletions that ended proximal to these two genes. The two
children with the more distal deletions, extending to and including
HMGA2 and LEMD3, were severely growth retarded, with growth of
four SDS below the mean. Neither child had osteopoikilosis. The other
four children with more proximal deletions have much milder
evidence of growth retardation. Our cases confirm the association
between severe growth retardation and loss of HMGA2, and highlight
the possibility that cases of primordial dwarfism and/or Silver–Russell
syndrome with developmental delay should be investigated for
deletions within this region.
CLINICAL CASES
Case 1
The child, a girl, was born by caesarean section at 36 weeks weighing
2.05 kg at birth (Figure 1a). Her head circumference was 32 cm and
length was 45 cm. Her failure to thrive resulted in a provisional
diagnosis of Silver—Russell syndrome being made, although there
was no asymmetry, no cafe´ au lait patches and no history of excess
sweating. She sat independently at 18 months and ‘bottom shuffled’
until the age of 4 years, when she eventually walked. She has speech
delay, although this is predominantly expressive. At the age of 11 years
she is moderately developmentally delayed and is quite hyperactive,
although she can concentrate. She can speak full sentences in both
English and Polish; however, she had significant expressive speech
delay as a young child. She cannot read or write. She can recognise
colours, is good at jigsaws and likes singing and music. She can dress
herself and manage basic hygiene. She is described as a naughty
but popular child. She suffers from gastrointestinal reflux and
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previously suffered from constipation. On examination at the age of
7 years and 11 months, her Ht was 101.5 cm (4.21 SDS), Wt was
14.2 kg (4.42 SDS) and OFHC was 53.2 cm (+1.13 SDS). Her
mother and father are 161 cm and 176 cm tall, respectively. She has
relative macrocephaly. Her height velocity has been 3–4 cm per year.
Her leg length (2.4 SDS) is greater than her sitting height (4.9 SDS).
She has a convergent squint, a high nasal bridge, long eyelashes and a
cupid’s bow. She has clinodactyly and her terminal phalanges are
broad. She had fifth finger clinodactyly bilaterally. She has truncal
obesity since the age of 10 years, with her weight velocity being greater
than her height velocity.
Clinical investigations
The following investigations were normal: U and E, TFTs, routine
chromosome analysis, uniparental disomy for chromosome 7, MLPA
telemore testing, IGF 1 18.7 nmol/l (12–50) and IGFBP3 2.6mg/l
(1.3–4.66). Cortisol levels were measured on several occasions and
were always within normal limits and she produced a good cortisol
response to insulin-induced hypoglycaemia. A small anterior pituitary
gland was seen on brain MRI scan and no other abnormality was
detected. A skeletal survey noted a mild scoliosis but there was no
evidence of osteopoikilosis. Bone age was 8 years and 10 months at a
chronological age of 10.5 years. An insulin tolerance test revealed
growth hormone deficiency.
Overnight growth hormone levels were subnormal for growth
hormone secretion with only two peaks 43.3 within 12h (4.5 and
4.66mg/l). A normal result is established if at least three peaks
per night are identified.5 As this is less than the normal range,
she has recently been started on growth hormone treatment. It is
noteworthy that this child suffered a fracture to her left frontal bone
as a young child and this may have been a contributory factor to
the growth hormone deficiency.
Case 2
The second child, a girl was born weighing 1.93 kg at 37+4 weeks
(Figure 1b). She failed to thrive from birth. She was found to have an
atrial septal defect. She is severely growth retarded with growth
parameters as follows: at 3 months: Ht 50.2 cm (44 SDS),
Wt 4.0 kg (3 SDS), OFHC 37.5 cm (2 SDS); at 17 months: Ht
67.5 cm (44 SDS), Wt 7.5 kg (4 SDS), head circumference 45.5 cm
(1.5 SDS); at 3 years: Ht 81 cm (43.1 SDS), Wt 9.9 kg (3.4 SDS).
She weighed only 10 kg at 3 years and 8 months of age. The mother’s
height is 160 cm and her father’s height is 175 cm. She fails to thrive
and is currently being fed by gastrostomy. She has relative macro-
cephaly and is hyperactive. She has a bilateral convergent squint. She
has an aversion to food and very rarely consumes a drink. She sat
independently at 1 year and started walking at the age of 2 years. She is
incapable of speech but can express herself by showing what she wants.
She has had several ear infections and pneumonia. She has the
following dysmorphic signs: a short-broad neck, frontal bossing,
hypertelorism, upslanting palpebral fissures, a high nasal bridge and
a short nose. The philtrum is flat, the upper lip is thin and her mouth
Case 1 front & side profile
Case 2
Case 3
Case 4.
Case 6
Figure 1 Clinical photographs of five affected individuals with 12q14 deletions. Informed consent was obtained for publication of photographs of cases
1–4 and 6.
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is rather big. She has a micrognathia and low set ears. She has a single
palmar crease on the left hand and a sacral dimple. X-ray at the age of
3 years showed no signs of skeletal/bone abnormalities. She has been
diagnosed with moderate mental retardation with autism and sig-
nificant behavioural difficulties. The 12q14 microdeletion was not
present in the mother, but DNA from a phenotypically normal father
was not available for testing.
Case 3
The third case, a male, was born at 39 weeks weighing 3.6 kg
(Figure 1c). He had feeding difficulties as a neonate. At 4½ years
of age, his Ht was 101 cm (0.6 SDS), Wt was 15kg (1.12 SDS) and
head circumference was 51.5 cm (+0.79 SDS). He has moderate global
developmental delay and no speech at the age of 6 years. He walked
at 2½ years. He has a mild degree of pulmonary stenosis and a
progressive pectus deformity. Dysmorphic features include long eye-
lashes, low post hairline, frontal hair whorl and mild brachydactyly.
He has small joint hypermobility and poor oromotor control, and
constantly dribbled until the age of 4 years. The 12q14 microdeletion
occurred as a de novo event.
Case 4
The fourth case, a male, was born at 36 weeks weighing 1.9 kg
(Figure 1d). He was diagnosed with pyloric stenosis for which he
underwent surgery. He is severely developmentally delayed, hyper-
active and is thought to be on the autistic spectrum. At the age of
2 years and 3 months, his growth parameters were as follows:
Ht 83.5 cm (0.66 SDS), Wt 12.7 kg (0.05 SDS) and OFC 48.5 cm.
At the age of 2 years and 9 months he spoke no words. His growth
parameters at the of age 2 years and 11 months were as follows: OFC
48.5 cm, 25th centile; Ht 87.5 cm 50th centile; and Wt IUGR 4 lbs
11oz, 50th centile at 36 weeks. At the age of 5 years and 8 months, his
height was 105.5 cm and weight was 18.5 kg. It was not possible to
measure his OFHC. He has a history of several upper respiratory tract
infections. Dysmorphic features include a marked widow’s peak,
upslanting palpebral fissures and a pouty lower lip with protruding
tongue. He has strikingly short, broad fingers and toes, particularly
his thumbs. His genitalia are normal and other examinations were
unremarkable. At 6 years and 5 months he has much more interaction
with people around him. He has developed the use of single words and
is using sounds in addition to defining by action very well. However,
he is still extremely active and still in nappies. He is not interested in
food and seems to need only a little sleep. He has started to bite his
arms a bit and get frustrated with communication at times. Skeletal
survey showed broad spatulate tips to distal phalanges. His parents
declined genetic testing but were phenotypically normal.
Case 5
The pregnancy was complicated by a car accident at 28 weeks. The
baby, a boy was born weighing 2.89 kg at 36 weeks (Figure 1e). He was
admitted to SCBU overnight and fed rather poorly from the begin-
ning. At the age of 8 months he was diagnosed with global develop-
mental delay. He sat at 8 months and walked at 18 months. He has
marked speech delay. He is now 20 years old and attends a special
school. Dysmorphic features include upslanting palpebral fissures,
pinched nose, high palate, flat face, broad hands, flat feet and 2/3
syndactyly. A provisional earlier diagnosis of Lujan Fryns was made.
Growth at 17.7 years was as follows: Ht 161.9 cm (0.04 SDS), Wt
51.1 kg (0.80 SDS) and OFC 53.2 cm (0.99 SDS). He had an atrial
septal defect that required closure. The 12q14 microdeletion occurred
as a de novo event.
Case 6
The sixth case (Figure 1f) was the second child of non-consangui-
neous parents, born at term by emergency caesarean section for fetal
distress, weighing 2.85 kg. This followed an uncomplicated pregnancy.
There were no feeding problems. There were concerns from the
beginning as the parents noticed that he showed a delay in achieving
his milestones. At 2 years and 6 months, he was diagnosed to have a
moderated sub-aortic stenosis. At 4 years and 4 months, he was
assessed to have moderate global developmental delay and was still
incapable of putting two words together. He has hypermetropia. His
growth parameters were as follows: Ht 95 cm (2.3 SDS), Wt 15.1 kg
(1.1 SDS) and OFHC 49 cm (2.3 SDS). Dysmorphic features
include brachycephaly, deep set eyes, bilateral low set posteriorly
rotated ears, short nasal bridge with an upturned nose and a long
simple philtrum with a thin upper lip. He was seen to have focal
cortical dysplasia in the insular cortex on brain MRI scan. The 12q14
microdeletion occurred as a de novo event.
METHODS
Microarray analysis
Following initial diagnostic investigations by karyotyping and multiplex
ligation-dependent probe amplification (MLPA (subtelomere kits P036D and
P070) MRC Holland) in which no imbalances were detected, whole genome
screening was carried out using whole-genome 0.5Mb ‘CytoChip’ microarrays
(BlueGnome, Cambridge, UK) for cases 1 and 5, SNP6.0 analysis for case 2
(Affymetrix, Santa Clara, CA, USA), 44K oligo (Agilent, Santa Clara, CA, USA)
microarray for cases 3–4 and 135K oligo (Roche-Nimblegen, Madison, WI,
USA) for case 6. Microarray procedures were carried out on the respective
microarray platforms using standard procedures. Higher resolution screening
using a 135K oligonucleotide arrays (Roche-Nimblegen) was subsequently used
to more precisely define deleted breakpoints for case 1 and 3–6. To refine
breakpoints in case 2, an Affymetrix Genome-Wide SNP Array 6.0 (Affymetrix)
was carried out in accordance with the manufacturer’s instructions. All
CytoChip BAC microarrays were scanned at 10-mm resolution using a GenePix
Pro 5.0 array scanner Axon (Molecular Devices, Sunnyvale, CA, USA) and
analysed using BlueFuse for Microarrays analysis software version 3.4
(BlueGnome). All oligo and SNP arrays were carried out according to the
manufacturer’s protocols, scanned at 2–5mm, and analysed using SignalMap v1.9
(135K), DNA Analytics v4.0.76 (44K), or Genotyping Console v4.0 (SNP6.0).
Confirmation of array-CGH results
FISH techniques were carried out on metaphase spreads prepared from
peripheral blood for patients 1, 3 and 5 and for both parents wherever possible,
using standard techniques.6 Microdeletions of 12q14 were confirmed in each
case using BAC probes within each respective deleted region. In case 2, three
specifically designed MLPA probes were designed to cover the region
of interest.7 Data analysis was carried out with GeneMarker software 1.85
(Softgenetics, State College, PE, USA). The parents of case 4 declined genetic
testing but were identified as being phenotypically normal. Quantitative (real-
rime) PCR (qPCR) was carried out in quadruplicate (case 5 only) and data
were analysed using the relative quantification method (ddCT).
8 The control
used was pooled DNA from 12 normal individuals from the blood bank, and
the reference/endogenous control was the single copy RNase P. Microarray-
CGH investigations using a Roche-Nimblegen 135K array were carried outfor
confirmatory studies in case 6.
RESULTS
Detection of deletions encompassing 12q14
The deletions in all six affected individuals were initially detected as
part of an array-CGH screen for cryptic rearrangements in patients
with moderate–severe learning disability and/or congenital anomalies
following normal karyotype and subtelomere MLPA analysis. In total,
we had six positive cases out of 2538 cases referred with developmental
delay for array analysis, giving a frequency of 1 in 423 cases. It is not
12q14 microdeletion syndrome
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possible to estimate an overall frequency of this deletion syndrome as
the cases tested by array are a biased cohort, selected by clinical
geneticists and would not represent the developmental delay popu-
lation in general. High-resolution oligo/SNP arrays were used to
estimate the minimum size of the deletion breakpoints (median
probe spacing B12 524 bp (135K), and B40 000 bp (44K), B680 bp
(SNP6.0)): case 1, 56 192 860–66 309 484 bp; case 2, 55 728 406–
65850 933 bp; case 3, 55 704 299–58779 521 bp; case 4, 55 723 270–
61 759877 bp; case 5, 55 508 340–56 797 233bp; and case 6, 55344 266–
58329 514 (NCBI Human Genome Build 36). The deleted region in
each of the six cases (Figure 2) overlaps significantly with previously
reported cases with microdeletions of this region.1–4 In the current
study, the chromosomal range of deletions extends from 12q13.3q15.
With the exception of case 5 in the current study, cases 1–4 and 6 carry
overlapping deletions of variable size but comprise chromosomal
bands 12q13.3q14.1. No other copy number variants were identified
elsewhere in the genome in the six cases that have not been previously
identified as high-frequency CNVs in normal population studies
according to the Database of Genomic Variants (http://projects.
tcag.ca/variation/). FISH verification experiments were carried out
on metaphase spreads from cases 1, 3 and 5 (MLPAwas carried out in
case 2, parents were unavailable in case 4 and array-CGH was used for
confirmation in case 6), to validate each copy number imbalance as
detected by array-CGH. All FISH probes used to confirm the array-
CGH findings for each of the cases were within each deleted 12q
region. Normal FISH signals for each probe were seen for parental
cases 1, 3 and 5 (data not shown) confirming that these three cases
were de novo deletions of the 12q13.3q15 region. For case 2, the
microdeletion was not identified in the mother, and the father was not
available for testing. The parents of case 4 declined genetic testing.
qPCR analysis using the TaqMan/Universal Probe Library sequence-
specific probes to RDH16, together with FISH was used to confirm
the de novo deletion in case 5. Microarray analysis using a 135k oligo
array (Roche-Nimblegen) was carried out to confirm a de novo
deletion in case 6.
DISCUSSION
In the current communication, we report further six cases with
deletions encompassing 12q14 which brings the total number to
12 reported cases. At a time when phenotypic variability is often
associated with newly identified microdeletion syndromes, 12q14
deletions have been reported as a relatively uniform and constant
phenotype of low birth weight, poor feeding in infancy, short stature
and learning disability.1–4 There have been reports of some cases
presenting with osteopoikilosis and skin lesions as well.3 A further case
reported by Jurenka and van Allen,9 presenting with short stature,
learning disability and a mixed sclerosing bone dysplasia, is also
suspected of having a 12q14 microdeletion by Mari et al.2 The
12q14 deletions in our cases varied in size from 1.28 to 10.12Mb.
The apparent lack of low copy repeats near the breakpoints in each
of our cases indicates that the underlying genetic mechanism of non-
homologous end joining may be responsible for recurrent deletions
within this region. The number of HGNC genes within the deleted
regions of all six cases ranged from 35 to 58 with 15–39 OMIM-listed
genes. Although there is substantial genomic overlap with the pre-
viously reported 12q14 microdeletion cases, it should be reported that
the shortest region of overlap (SRO) between all six cases reported in
this communication differs substantially from the SRO of the reported
Figure 2 Schematic illustration of the six 12q14 deletions detected by array-CGH using the Ensembl browser. Deleted regions for the respective cases in
this communication are shown as red bars. The colour reproduction of this figure is available on the html full text version of the manuscript.
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cases in literature. This will inevitably explain phenotypic variation
between cases. The SRO of the previously reported 12q14 micro-
deletion cases includes HMGA2. Genotype–phenotype correlations
are difficult to ascertain, as only cases 1 and 2 are severely
growth retarded; however, but common characteristics seen include
moderate–severe learning disability, speech delay and congenital heart
defects (not known for case 4); therefore, so it is possible that deletion
of one or more of these genes could be responsible for any of these
aspects of the phenotype (see Table 1). DCTN2 and KIF5A have been
associated with disruptions in axonal transport;10,11 therefore, in
theory, haploinsufficiency could account for the neurodevelopmental
anomalies seen in these cases. Congenital heart defects have not been
reported in any of the six reported 12q14 microdeletions in literature,
which suggests that the candidate cardiac gene lies upstream of the
5¢ ends of previously reported cases. The largest region of overlap seen
in our cases was between case 1 and 2 comprising 9.65Mb, and
includes both HMGA2 and LEMD3.
The first report of the 12q14 microdeletion syndrome by Menten in
20071 described three patients with a deletion of 12q14 who presented
with growth retardation and osteopoikilosis. There was a 3.44-Mb
common deleted region that contained LEMD3, the causal gene for
osteopoikilosis.12 However, growth retardation, failure to thrive and
learning disability have not been reported in patients with osteo-
poikilosis or melorheostosis. Mari et al2 described a case with
primordial dwarfism and a smaller deletion of the 12q14.4 region.
The child, a boy, had severe prenatal and postnatal growth failure and
mild developmental delay. There was a history of poor feeding and
failure to thrive, similar to the phenotype of primordial dwarfism or
severe Silver–Russell syndrome (SRS). There was no evidence of
osteopoikilosis but this child’s deletion started distally to that of the
cases in Menten et al1 and did not include LEMD3. Buysse et al3
described two children, one of whom had an intragenic deletion of
HMGA2 and short stature, providing evidence that HMGA2 is the
likely growth gene. HMGA2 lies at 12q14.3, which would explain the
normal growth in our cases 3–6 whose deletion ended proximally.
Spengler et al4 identified one further case with a 12q14 deletion in a
series of 20 children with a diagnosis of SRS. This child’s deletion
included HMGA2 and LEMD3 although he had no evidence of
osteopoikilosis. Cases in which HMGA2 remains intact had growth
within the normal centiles. This supports the proposal that HMGA2 is
the most significant gene associated with growth in this region. Loss of
function of HMGA2 in the mouse results in the pygmy phenotype that
combines prenatal and postnatal growth failure, with resistance to the
adipogenic effect of overfeeding. As such it has been suggested that
haploinsufficiency of HMGA2 could be associated with both reduced
growth and poor feeding, failure to thrive and lack of adipose tissue,
which has been reported in some cases.2 This would not explain the
poor feeding and failure to thrive that was seen in cases 3–6 in this
report in which HMGA2 was not shown to be deleted.
Interestingly, case 1 had documented low overnight growth
hormone levels. As this child had a significant head injury resulting
in a frontal fracture as a baby, it is difficult to determine whether the
low growth hormone levels are related to the deletion or are a result of
the head injury, or perhaps a combination of both events. This child
has just recently commenced growth hormone therapy and we wait to
see how this affects growth. The case reported by Mari et al2 had been
treated with growth hormone without any obvious benefit. Growth
hormone levels in the other cases have not been documented. There
were some dysmorphic features common to cases 1–4 including, a
cupid’s bow upper lip. Two of the children (cases 1 and 3) had similar
facial dysmorphism with long eyelashes and a cupid’s bow. A prog-
nathic appearance is also present in cases 1–3. There was no evidence
of osteopoikilosis in any of our cases despite a deletion of LEMD3
in cases 1 and 2. Five of the six cases had congenital heart anomalies.
Two cases had an atrial septal defect (case 2 and 5), one had
pulmonary stenosis (case 3), one had sub-aortic stenosis and case 1
presented with a patent ductus. One child had pyloric stenosis, but
all except case 6 had feeding difficulties. Interestingly, severe speech
delay was noted in cases 2–6. Case 1, having expressive speech
delay early on, can currently speak full sentences in both Polish and
English at the age of 11 years. Two of the cases (2 and 4) were also
identified as having ‘autistic features’. The dysmorphism in these
children is subtle. They all had a cupid’s bow. Cases 1 and 2 had
deep set eyes and a squint and these two children have a very similar
facial appearance. The dysmorphism in the other four cases was
subtle. All cases except case 6 had a tall forehead. Cases 1, 3, 4
and 6 had arched eyebrows.
We conclude that the 12q14 microdeletion syndrome is a recurrent
deletion syndrome with a dysmorphic phenotype, which may be
recognisable in some cases. One needs to consider the diagnosis in
children with severe growth retardation and developmental delay.
Our cases, particularly cases 3–6, whose growth was within normal
centiles and whose deletion ended proximal to HMGA2, provide
further evidence that HMGA2 is a good candidate gene for growth
retardation. We would recommend growth hormone level measure-
ments in other cases with deletions of HMGA2 to determine whether
Table 1 Summary of the clinical features presented in six patients with deletion of 12q14
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Sex F F M M M M
Birth weight (kg) 2 kg at 36 weeks 1.9 at 37+4 weeks 3.6kg at 39 weeks 1.9 at 36 weeks 2.9 at 36 weeks 2.86 at 40 weeks
Development Moderate delay Severe delay Moderate delay Severe delay Moderate delay Moderate delay
Behaviour Pleasant and friendly
personality
Autism Autism
Feeding Poor feeder
gastrointestinal reflux
Poor feeder
gastrostomy fed
Poor feeder Pyloric stenosis Poor feeder Normal feeding
Malformations ?patent ductus Atrial septal defect Pulmonary stenosis and
pectus excavatum
Atrial septal defect Sub-aortic stenosis
Eyes Convergent squint Convergent squint Hypermetropia
Speech Expressive speech delay No speech No speech age 6 years Single words
aged 6 years
Marked speech delay Speech delay
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growth hormone deficiency is a common finding. Further testing for
loss of function mutations in HMGA2 is also required to test for
idiopathic short stature.
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